inVentiv Health has taken over contract research organization (CRO) i3, a provider of a range of clinical development services pharmaceutical, biotech and medical device industries.
Subscribe to our email newsletter
Following the acquisition, inVentiv Health’s clinical segment comprises i3, along with inVentiv’s existing clinical businesses and PharmaNet Development Group.
i3 CEO Glenn Bilawsky said for their clients, this will mean expanded clinical resources and expertise in the US and throughout the world to meet their needs.
"For our employees, it will mean exciting new opportunities to actively participate in building a true company," Bilawsky said.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.